Bayer is bringing its Roundup/glyphosate liability case before the U.S. Supreme Court, with CEO Bill Anderson attending the hearing directly. At the company's annual shareholder meeting, investors are demanding a fast resolution to years of costly litigation. A second consecutive dividend suspension is on the table if legal costs continue to mount.
Bayer's stock has been weighed down for years by glyphosate lawsuit liabilities that have cost the company tens of billions since its 2018 Monsanto acquisition. A Supreme Court ruling against Bayer could cement unlimited future liability, pressuring the stock and potentially forcing a breakup of the company. A favorable ruling, however, could act as a significant re-rating catalyst for BAYRY and the broader shares.
U.S. Supreme Court oral arguments on Bayer's glyphosate preemption case (scheduled spring 2025 term). Bayer Annual General Meeting: April 25, 2025. Supreme Court ruling expected by end of June 2025.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief